Using ex vivo avatars to understand immune reactivation in cancer
Findings call for a change in tumour categorisation, from a cell-of-origin to a tumour microenvironment-associated holistic approach
CHIP clones in solid tumours: therapeutic targets or bystander phenomena?
Ongoing research will help to clarify how CHIP clones may be used to guide therapy for patients with solid tumours
Which immune cell type is it best to target therapeutically in brain tumours?
Research is getting closer to the development of patient-specific tailored treatment approaches for brain tumours, thanks to increased understanding of the tumour microenvironment, including the critical importance of the immune system